

References for Podcast: (Met)formulating an approach to antipsychotic-induced weight gain

1. Government of Canada. Schizophrenia in Canada [Internet]. Canada. [2020 July 07; cited 2022 Sep 12]. Available from: <https://health-infobase.canada.ca/datalab/schizophrenia-blog.html?text=About%2050%20per%20100%20C000%20Canadians%20are%20newly%20diagnosed%20with%20schizophrenia>.
2. Stroup TS and Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. In: *UpToDate*. Stein MB (Ed), UpToDate, Waltham, MA. (Accessed 2022 Sep 12). Available from: https://www.uptodate.com/contents/schizophrenia-in-adults-maintenance-therapy-and-side-effect-management?search=psychosis%20treatment&topicRef=130944&source=see_link#H2945246380
3. Marder S. Psychosis in adults: Initial Management. In: *UpToDate*. Stein MB (Ed), UpToDate, Waltham, MA. (Accessed 2022 Sep 12). Available from: https://www.uptodate.com/contents/psychosis-in-adults-initial-management?sectionName=INITIAL%20MANAGEMENT&search=psychosis%20treatment&topicRef=14805&anchor=H4035521878&source=see_link#H4035521878
4. Pérez-Iglesias R, Martínez-García O, Pardo-García G, Amado JA, García-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. *Int J Neuropsychopharmacol*. 2014 Jan;17(1):41-51. doi: 10.1017/S1461145713001053. Epub 2013 Oct 8. PMID: 24103107.
5. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. *J Psychopharmacol*. 2013 Apr;27(4):358-65. doi: 10.1177/0269881112473789. Epub 2013 Jan 23. PMID: 23343595.
6. Zheng W, Zhang QE, Cai DB, Yang XH, Ungvari G, Ng C, et al. Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials. *Pharmacopsychiatry*. 2019 Jan;52(01):24–31.
7. Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. *Expert Opinion on Drug Safety*. 2020 Mar 3;19(3):295–314.
8. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *The Lancet Psychiatry*. 2020 Jan;7(1):64–77.
9. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications: Weight gain in FEP patients. *Early Intervention in Psychiatry*. 2016 Jun;10(3):193–202.
10. Martene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. *Expert Opinion on Drug Safety*. 2019 Dec 2;18(12):1149–60.
11. Wang Y, Wang D, Cheng J, Fang X, Chen Y, Yu L, et al. Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis. *J Psychopharmacol*. 2021 Sep;35(9):1111–9.

12. Cooper SJ, Reynolds GP, With expert co-authors (in alphabetical order):, Barnes T, England E, Haddad P, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. *J Psychopharmacol*. 2016 Aug;30(8):717–48.
13. Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, et al. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. *Transl Psychiatry*. 2021 Jun;11(1):219.
14. Ballon JS, Pajvani UB, Mayer LE, Freyberg Z, Freyberg R, Contreras I, et al. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. *J Psychopharmacol*. 2018 May;32(5):533–40.
15. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. *BMC Psychiatry*. 2016 Dec;16(1):341.
16. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. *Schizophr Bull*. 2014 Nov;40(6):1385–403. doi: 10.1093/schbul/sbu030. Epub 2014 Mar 17. PMID: 24636967; PMCID: PMC4193713.
17. Tang C, Chua YC, Abdin E, Subramaniam M, Verma S. Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study. *IJERPH*. 2021 Dec 23;19(1):137.
18. Siskind D, Russell AW, Suetani S, Flaws D, Kisely S, Moudgil V, et al. CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine. *Therapeutic Advances in Psychopharmacology*. 2021 Jan;11:204512532110452.
19. Stogios N, Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, et al. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update. *Biological Psychiatry*. 2020 May;87(9):S357.
20. Costa-Dookhan K, Agarwal SM, Chintoh A, Mackenzie N, Casuccio-Treen Q, Remington G, et al. S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS.
21. Yunilaynen OA, Oleichik IV, Sizov SV, Baranov PA, Starostina EG. Efficacy of metformin for treatment and prevention of antipsychotic-induced overweight and obesity in women: an open-label, randomized, prospective placebo-controlled study. *Obes metabol*. 2021 Jul 24;18(2):198–209.
22. Fitzgerald I, O'Connell J, Keating D, Hynes C, McWilliams S, Crowley EK. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. *Evid Based Mental Health*. 2022 Feb;25(1):15–22.
23. de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers CH, et al. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. *BMC Psychiatry*. 2021 Dec;21(1):4.